TG Therapeutics Inc (TGTX)
Profitability ratios
Return on sales
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Gross profit margin | 38.10% | -2,421.33% | -1,818.10% | -70,853.95% | -9,786.18% |
| Operating profit margin | 9.33% | -6,924.20% | -5,154.28% | -179,996.05% | -111,220.39% |
| Pretax margin | 5.91% | -7,121.54% | -5,204.08% | -183,803.29% | -113,730.26% |
| Net profit margin | 5.73% | -7,121.54% | -5,204.08% | -183,803.29% | -113,730.26% |
TG Therapeutics Inc's profitability ratios show a fluctuating performance over the past five years. The gross profit margin improved significantly from negative values in 2020 and 2021 to a positive 38.10% in 2023, indicating better control over direct costs of goods sold. Operating profit margin also rebounded to 9.33% in 2023 from extremely negative figures in the previous years, indicating enhanced operational efficiency. The pretax margin and net profit margin followed a similar trend, turning positive in 2023 after being deeply negative in the earlier years. Overall, the company's profitability ratios demonstrate a positive turnaround in recent years, implying better cost management and operational performance.
Return on investment
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 6.26% | -99.62% | -90.82% | -43.73% | -103.71% |
| Return on assets (ROA) | 3.84% | -102.46% | -91.70% | -44.66% | -106.05% |
| Return on total capital | 9.85% | -148.66% | -113.43% | -51.91% | -247.96% |
| Return on equity (ROE) | 7.90% | -338.53% | -146.78% | -53.79% | -447.68% |
TG Therapeutics Inc has shown improvement in its profitability ratios over the past few years.
The Operating Return on Assets (Operating ROA) has rebounded positively, with a significant increase from negative percentages in 2020 and 2021 to 6.26% in 2023. This indicates that the company is generating profits from its core operations more efficiently in relation to its assets.
The Return on Assets (ROA) has also shown improvement, moving from negative figures in 2020 and 2021 to a positive 3.84% in 2023. This suggests that the company is generating a higher level of profit relative to its total assets.
The Return on Total Capital has also increased significantly over the years, reaching 9.85% in 2023, indicating that the company is utilizing its total capital more effectively to generate returns for its stakeholders.
Lastly, the Return on Equity (ROE) has experienced a positive trend, with a notable improvement from negative figures in prior years to 7.90% in 2023. This suggests that the company is delivering better returns to its equity shareholders for the equity they have invested in the business.
Overall, these improvements in profitability ratios indicate that TG Therapeutics Inc has been able to enhance its operational efficiency and generate higher returns for its stakeholders in recent years.